AngioScore waits on FDA decision as it sets sights on Abbott catheter patent
This article was originally published in Clinica
Executive Summary
AngioScore is urging the US FDA not to extend a rapid exchange angioplasty catheter patent belonging to Abbott Laboratories, in a bid to gain control of the lucrative rights itself.